Arabela Sanz-Alcázar

Arabela Sanz-Alcázar

Auto-generated profile, based on publicly available information

Arabela Sanz-Alcázar

Dept. Ciències Mèdiques Bàsiques, Facultat de Medicina, Universitat de Lleida, Av. Alcalde Rovira Roure 80, Lleida, 25198, Spain; Institut de Recerca Biomèdica de Lleida - Fundació Dr. Pifarré, IRBLleida (ROR: 03mfyme49), Av. Alcalde Rovira Roure 80, Lleida, 25198, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2024 in Redox Biology
Verified
Journal Article
Open access
ASArabela Sanz-Alcázar
Arabela Sanz-Alcázar
MPMarta Portillo-Carrasquer
Marta Portillo-Carrasquer
FDFABIEN DELASPRE
FABIEN DELASPRE
MPMaria Pazos-Gil
Maria Pazos-Gil
JTJordi Tamarit
Jordi Tamarit
ECElisa Cabiscol
Elisa Cabiscol
Friedreich ataxia (FA) is a rare neurodegenerative disease caused by decreased levels of the mitochondrial protein frataxin. Frataxin has been related in iron homeostasis, energy metabolism, and oxidative stress. Ferroptosis has recently been shown to be involved in FA cellular degeneration; however, its role in dorsal root ganglion (DRG) sensory neurons, the cells that are affected the most and the earliest, is mostly unknown. In this study, we used primary cultures of frataxin-deficient DRG neurons as well as DRG from the FXNI151F mouse model to study ferroptosis and its regulatory pathways. A lack of frataxin induced upregulation of transferrin receptor 1 and decreased ferritin and mitochondrial iron accumulation, a source of oxidative stress. However, there was impaired activation of NRF2, a key transcription factor involved in the antioxidant response pathway. Decreased total and nuclear NRF2 explains the downregulation of both SLC7A11 (a member of the system Xc, which transports cystine required for glutathione synthesis) and glutathione peroxidase 4, responsible for increased lipid peroxidation, the main markers of ferroptosis. Such dysregulation could be due to the increase in KEAP1 and the activation of GSK3β, which promote cytosolic localization and degradation of NRF2. Moreover, there was a deficiency in the LKB1/AMPK pathway, which would also impair NRF2 activity. AMPK acts as a positive regulator of NRF2 and it is activated by the upstream kinase LKB1. The levels of LKB1 were reduced when frataxin decreased, in agreement with reduced pAMPK (Thr172), the active form of AMPK. SIRT1, a known activator of LKB1, was also reduced when frataxin decreased. MT-6378, an AMPK activator, restored NRF2 levels, increased GPX4 levels and reduced lipid peroxidation. In conclusion, this study demonstrated that frataxin deficiency in DRG neurons disrupts iron homeostasis and the intricate regulation of molecular pathways affecting NRF2 activation and the cellular response to oxidative stress, leading to ferroptosis.

21 December 2023 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
ASArabela Sanz-Alcázar
Arabela Sanz-Alcázar
EBElena Britti
Elena Britti
FDFABIEN DELASPRE
FABIEN DELASPRE
MMMarta Medina-Carbonero
Marta Medina-Carbonero
MPMaria Pazos-Gil
Maria Pazos-Gil
ECElisa Cabiscol
Elisa Cabiscol
Friedreich ataxia (FA) is a rare, recessive neuro-cardiodegenerative disease caused by deficiency of the mitochondrial protein frataxin. Mitochondrial dysfunction, a reduction in the activity of iron-sulfur enzymes, iron accumulation, and increased oxidative stress have been described. Dorsal root ganglion (DRG) sensory neurons are among the cellular types most affected in the early stages of this disease. However, its effect on mitochondrial function remains to be elucidated. In the present study, we found that in primary cultures of DRG neurons as well as in DRGs from the FXN I151F mouse model, frataxin deficiency resulted in lower activity and levels of the electron transport complexes, mainly complexes I and II. In addition, altered mitochondrial morphology, indicative of degeneration was observed in DRGs from FXN I151F mice. Moreover, the NAD + /NADH ratio was reduced and sirtuin activity was impaired. We identified alpha tubulin as the major acetylated protein from DRG homogenates whose levels were increased in FXN I151F mice compared to WT mice. In the mitochondria, superoxide dismutase (SOD2), a SirT3 substrate, displayed increased acetylation in frataxin-deficient DRG neurons. Since SOD2 acetylation inactivates the enzyme, and higher levels of mitochondrial superoxide anion were detected, oxidative stress markers were analyzed. Elevated levels of hydroxynonenal bound to proteins and mitochondrial Fe 2+ accumulation was detected when frataxin decreased. Honokiol, a SirT3 activator, restores mitochondrial respiration, decreases SOD2 acetylation and reduces mitochondrial superoxide levels. Altogether, these results provide data at the molecular level of the consequences of electron transport chain dysfunction, which starts negative feedback, contributing to neuron lethality. This is especially important in sensory neurons which have greater susceptibility to frataxin deficiency compared to other tissues.

22 September 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MPMarta Portillo-Carrasquer
Marta Portillo-Carrasquer
ASArabela Sanz-Alcázar
Arabela Sanz-Alcázar
FDFABIEN DELASPRE
FABIEN DELASPRE
MPMaria Pazos-Gil
Maria Pazos-Gil
LOLuiza Oliveira-Jorge
Luiza Oliveira-Jorge
ECElisa Cabiscol
Elisa Cabiscol
Friedreich ataxia (FA) is a neurodegenerative disease characterized by degeneration of the large sensory neurons and spinocerebellar tracts, muscle weakness, and hypertrophic cardiomyopathy. It is caused by a deficiency of the mitochondrial protein frataxin, leading to iron dyshomeostasis, defective energy production, and oxidative stress. Peroxisome proliferator-activated receptor gamma (PPARγ) and nuclear factor erythroid 2-related factor 2 (NRF2) signaling pathways play crucial roles in regulating mitochondrial function and protecting against oxidative stress, and their dysregulation contributes to neuronal degeneration in FA. In this study, we used frataxin-deficient primary cultures of dorsal root ganglia neurons to better understand the mechanism of action of leriglitazone, a novel brain-penetrant, full, and selective PPARγ agonist, by assessing the rescue of several cellular markers altered under frataxin deficiency. Leriglitazone improved most of the analyzed parameters, including cell survival, mitochondrial respiratory activity, iron homeostasis, and oxidative stress. Moreover, increased lipid peroxidation, a key marker of ferroptosis, was almost completely rescued by leriglitazone. NRF2 and PPARγ coactivator 1 alpha (PGC1α) levels that were decreased in frataxin-deficient neurons were normalized by leriglitazone. Interestingly, the combination of leriglitazone and the NRF2 activator omaveloxolone, a drug that has been approved to treat FA, was able to rescue both survival and mitochondrial function. In summary, our findings in this neuronal model suggest that targeting the PPARγ pathway with leriglitazone may be a promising therapeutic strategy for FA by improving mitochondrial function, bioenergetic cell alterations, and iron homeostasis. Likewise, a combination therapy with omaveloxolone may be an alternative for FA patients.

23 January 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MPMarta Portillo-Carrasquer
Marta Portillo-Carrasquer
ASArabela Sanz-Alcázar
Arabela Sanz-Alcázar
BSBegoña Sánchez-López
Begoña Sánchez-López
FDFABIEN DELASPRE
FABIEN DELASPRE
MPMaria Pazos-Gil
Maria Pazos-Gil
ECElisa Cabiscol
Elisa Cabiscol
Friedreich ataxia (FA) is a rare, multisystemic neurodegenerative disorder caused by a deficiency of the mitochondrial protein frataxin. It is characterized by degeneration of the large sensory neurons in the dorsal root ganglia (DRG) and spinocerebellar tracts, leading to progressive neurodegeneration and muscle weakness. Frataxin deficiency induces iron dyshomeostasis, defective energy production, and oxidative stress, all regulated by NRF2. Omaveloxolone, an NRF2 activator, is currently the only approved therapy for FA; however, its effects on DRG neurons remain unknown. Here we used frataxin-deficient DRG neurons to better understand the drug's role in these sensory neurons. Omaveloxolone improved most of the analyzed parameters, including frataxin levels, cell survival, mitochondrial respiratory activity, iron homeostasis, oxidative stress, transferrin receptor 1 and glutathione peroxidase 4 levels, as well as the GSH/GSSG ratio. Moreover, lipid peroxidation, a key marker of ferroptosis that was increased in frataxin-deficient neurons, was almost completely rescued by omaveloxolone. Both total and nuclear NRF2 levels were decreased in frataxin-deficient neurons, and omaveloxolone treatment fully prevented this alteration. In addition, most of these results were validated in fibroblasts from FA patients. We also evaluated a combinatorial treatment using low doses of omaveloxolone together with honokiol, a SIRT3 activator with known neuroprotective properties. This combination enhanced cell survival and produced a synergistic effect increasing mitochondrial respiration in frataxin-deficient DRG neurons. In summary, these findings demonstrate the beneficial effects of omaveloxolone and further suggest that combination therapy with honokiol may provide an effective strategy for the treatment of FA, potentially mitigating adverse effects.

Verified
Journal Article
Open access
PDF file
MAManuel Rui Fernandes Azevedo Alves
Manuel Rui Fernandes Azevedo Alves
MPMaria Pazos-Gil
Maria Pazos-Gil
MMMarta Medina-Carbonero
Marta Medina-Carbonero
ASArabela Sanz-Alcázar
Arabela Sanz-Alcázar
FDFABIEN DELASPRE
FABIEN DELASPRE
JTJordi Tamarit
Jordi Tamarit
Friedreich’s ataxia is a neurodegenerative disease caused by mutations in the frataxin gene. Frataxin homologues, including bacterial CyaY proteins, can be found in most species and play a fundamental role in mitochondrial iron homeostasis, either promoting iron assembly into metaloproteins or contributing to iron detoxification. While several lines of evidence suggest that eukaryotic frataxins are more effective than bacterial ones in iron detoxification, the residues involved in this gain of function are unknown. In this work, we analyze conservation of amino acid sequence and protein structure among frataxins and CyaY proteins to identify four highly conserved residue clusters and group them into potential functional clusters. Clusters 1, 2, and 4 are present in eukaryotic frataxins and bacterial CyaY proteins. Cluster 3, containing two serines, a tyrosine, and a glutamate, is only present in eukaryotic frataxins and on CyaY proteins from the Rickettsia genus. Residues from cluster 3 are blocking a small cavity of about 40 Å present in E. coli’s CyaY. The function of this cluster is unknown, but we hypothesize that its tyrosine may contribute to prevent formation of reactive oxygen species during iron detoxification. This cluster provides an example of gain of function during evolution in a protein involved in iron homeostasis, as our results suggests that Cluster 3 was present in the endosymbiont ancestor of mitochondria and was conserved in eukaryotic frataxins.

6 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MPMaria Pazos-Gil
Maria Pazos-Gil
MMMarta Medina-Carbonero
Marta Medina-Carbonero
ASArabela Sanz-Alcázar
Arabela Sanz-Alcázar
MPMarta Portillo-Carrasquer
Marta Portillo-Carrasquer
LOLuiza Oliveira
Luiza Oliveira
JTJordi Tamarit
Jordi Tamarit
Friedreich Ataxia (FA) is a cardio-neurodegenerative disease caused by mutations in the frataxin gene, which result in low frataxin expression. It is well-established that frataxin deficiency affects iron homeostasis, but the tissue-specificity of these alterations is poorly understood. In this study, we have analyzed iron homeostasis alterations in the FXNI151F mouse model, which presents systemic frataxin deficiency and neurological defects resembling FA patients. Iron overload is observed in the brain from 21-week old FXNI151F mice, both males and females, and it does not further accumulate in older animals. It is also observed in livers from 39-week old mutant females, but not in males. Iron signaling is altered in all tissues: in brain and liver Iron Regulatory Protein 1 (IRP1) content is decreased, while in heart increased IRP2 and decreased specific aconitase 2 activity are observed. Remarkably, these cardiac alterations are partially restored in 39- week-old animals, suggesting that the heart is activating an iron-deficiency response to compensate for deficient iron-sulfur biogenesis. Our findings demonstrate that frataxin deficiency affects iron homeostasis in a time dependent and tissue-specific manner, and that the pathological mechanisms in FA comprise both iron accumulation and limited iron availability. Understanding this specificity is crucial for the design of iron-related therapeutic interventions aiming to improve FA symptomatology.